Navigation Links
Sensus Healthcare Announces the Formation of a Medical Advisory Board
Date:2/17/2011

ll carcinoma, as patients age and have one or more medical problems or are frail, non-surgical alternatives need to be explored. Photon RT is a therapeutic alternative to surgery or electron beam in elderly patients with certain tumor subtypes and locations. This is a time-honored, non-surgical modality which can be highly efficacious in select skin cancers yet still be extremely cost effective when compared to surgery or electron beam therapy. I am very optimistic in what the future holds in developing this technology to its fullest potential and the possibilities for our clinical community and patients." –Dr. Armand Cognetta (Medical Director, Sensus Healthcare)

"We are very excited to have the opportunity to collaborate with such a distinguished panel of experienced clinical experts on the subject of skin cancer treatment. We have a common objective; to provide patients and their physicians the choices that produce proven outcomes." –Joseph C. Sardano (President & CEO, Sensus Healthcare)

About Sensus Healthcare:Sensus Healthcare specializes in making proven non-melanoma skin cancer solutions more accessible to patients. Our dedicated superficial radiation therapy (SRT) systems are designed specifically to provide an alternative to surgical procedures for basal cell and squamous cell carcinomas. Our mobile, compact SRT-100™ systems are used widely by oncologists and dermatologists to bring non-melanoma skin cancer treatment to more patients in more settings. We also offer a professional skin care line, Sensus Skin Solutions™, through our physician SRT-100™ users for their patients.Contact:Vicky PerezPublic Relations561-922-5808 Ext 108vicky@sensushealthcare.com
'/>"/>

SOURCE Sensus Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sensus Healthcare Announces New Professional Skin Care Line - Sensus Skin Solutions™
2. Sensus Healthcare Announces Strategic Partnership With Flagship Solutions Group
3. Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer
4. GPhA Statement on the Introduction of the Bipartisan Biogenerics Consensus Bill: Promoting Innovation and Access to Life-Saving Medicine Act
5. New consensus on work-related asthma
6. Shionogi-ViiV Healthcare Starts Phase III Trial for 572-Trii Fixed-Dose Combination HIV Therapy
7. Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
8. Biodel Inc. to Present at 29th Annual JPMorgan Healthcare Conference on January 13th, 2011
9. Orexigen® Therapeutics to Present at JP Morgan Healthcare Conference
10. Cellular Dynamics International to Present at 29th Annual JPMorgan Healthcare Conference
11. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014 /PRNewswire-iReach/ -- Think Drinks are a neuroscience-backed drink ... term. They are the first functional focus beverage to ... an alternative to the temporary fix associated with energy ... July 29, 2014, with hopes to raise $50,000 over ... - http://photos.prnewswire.com/prnh/20140723/129697 Think Drinks ...
(Date:7/23/2014)... , 23 de julio de 2014 ... la Compañía) ha anunciado hoy una asociación con ... (ABIA o el Instituto), para el propósito ... dispositivo de terapia de señal bioeléctrica (el E-QURE ... El Instituto, que tiene una importante experiencia en ...
(Date:7/23/2014)... regulated information -- UCB today announced an important advance ... topline results from the latest Phase 3 study ... evaluate the efficacy and safety of brivaracetam ... to placebo, as adjunctive treatment in adult focal ... despite treatment with one or two concomitant antiepileptic ...
(Date:7/23/2014)... July 23, 2014 With the ability to ... resolution for more than 15 minutes, Fastec Imaging has brought ... of high speed imaging. “Finally, a high speed camera that ... use in our everyday lives.” proclaims Matt Kearney, VP of ... always been to demystify and simplify the traditionally complicated workflow ...
Breaking Biology Technology:truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3
... , NES-ZIONA, Israel, July 27, PROLOR ... that it has entered into an evaluation and option agreement with ... the Weizmann Institute of Science . Under ... from Yeda a license to develop a number of peptide drug ...
... , , , ... medicine is just in its adolescence today and I see our ... applications and global markets," stated Edward Pulwer, upon accepting the position ... Sechrist has been in business for over 30 ...
... , CALGARY, July 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... with the support of its contract manufacturer, SAFC Pharma(R), ... an initial 100-litre production run of REOLYSIN under cGMP ... of a series to be completed over the next ...
Cached Biology Technology:PROLOR Biotech Acquires License Option from Yeda for Development of Long-Acting Anti-Obesity Drug 2PROLOR Biotech Acquires License Option from Yeda for Development of Long-Acting Anti-Obesity Drug 3Sechrist Industries, World Leader in Hyperbaric Chambers, Announces Edward Pulwer as President/CEO 2Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R) 2
(Date:7/23/2014)... especially the young, are highly sensitive to temperature and ... temperatures within a narrow range. Recently published research led ... School of Arts and Sciences, is the first to ... hive in process similar to how humans and other ... , "This study shows how workers effectively dissipate ...
(Date:7/23/2014)... fur seals, alongside decades of in-depth monitoring, has ... change on a population of top-predators. Published in ... that the seals have significantly altered in accordance ... with climate conditions. Despite a shift in the ... passing down through generations, leaving the population in ...
(Date:7/23/2014)... experiments using tissue samples cultured from cystic fibrosis patients, ... UNC Marsico Lung Institute have shown that a new ... another CF drug. , The finding, published today in ... a mutant CFTR protein becomes unstable and loses its ... the two drugs. The research offers several insights into ...
Breaking Biology News(10 mins):How honey bees stay cool 2Genetic study shows major impact of climate change on Antarctic fur seals 2Genetic study shows major impact of climate change on Antarctic fur seals 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4
... University of Illinois animal sciences professor Harris Lewin ... Agriculture. He shares the prize with James R. Cook, ... are awarded each year, with recipients in agriculture, chemistry, ... selected Lewin for his "highly significant discoveries" in the ...
... Hospital of Philadelphia has announced the establishment of the ... A ceremony on Feb. 15 at the Hospital,s Ruth ... first holder of the chair, pediatric immunologist Jordan S. ... allow Dr. Orange to break new ground in his ...
... clues as to the habitats in which they are ... implications for predicting the effects of climate change on ... kingdom. Applying a method previously only used to ... scientists from the University of Cambridge can now determine ...
Cached Biology News:Illinois professor awarded 2011 Wolf Prize in Agriculture 2Modell Chair in Pediatric Immunology established 2Insects hold atomic clues about the type of habitats in which they live 2
...
... 4 deuterium atoms at the 3, 3', ... for use as an internal standard for ... LC-mass spectrometry. PGE1 is the theoretical cyclooxygenase ... is virtually undetectable in the plasma of ...
Direct ELISA Assay Diluent, 10 L...
... Immunogen: Synthetic peptide derived from ... junctophilin-3. Specificity: Specific for the ... Reactivity: Mouse (positive controls: mouse ... heart tissues). Applications: Western blotting ...
Biology Products: